insights_auto
Why is 2359 down 2,19%?
Dive Deeperchevron_right
2359:HKG
WuXi AppTec Ord Shs H
196,20 HKD
arrow_downward
-2,19%(-4,40) 1D
16-окт., 16:08:14 GMT+8 · HKD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 2359...
Open
203,80 HKD
High
209,00 HKD
Low
185,00 HKD
Mkt. cap
544,52 млд
Avg. vol.
3,91 млн
Volume
10,16 млн
Dividend
1,22%
Quarterly dividend
0,60 HKD
Ex-dividend date
2026-ж., 4-сен.
P/E ratio
23,98
52-wk high
219,20 HKD
52-wk low
96,70 HKD
EPS
8,18 HKD
No. of employees
36 миң
Open
203,80 HKD
High
209,00 HKD
Low
185,00 HKD
Mkt. cap
544,52 млд
Avg. vol.
3,91 млн
Volume
10,16 млн
Dividend
1,22%
Quarterly dividend
0,60 HKD
Ex-dividend date
2026-ж., 4-сен.
P/E ratio
23,98
52-wk high
219,20 HKD
52-wk low
96,70 HKD
EPS
8,18 HKD
No. of employees
36 миң
News stories
From web sources and news partners
ad-hoc-news.de
·
10 саат мурун
WuXi AppTec earns EcoVadis gold: what it means for WuXi AppTec stock
Profile
WuXi AppTec Co., Ltd. is a Chinese provider of contract research, development, and manufacturing, services for the pharmaceutical and life-sciences industry, headquartered in Shanghai, China. The company operates research and manufacturing facilities in Asia, North America, and Europe.
Founded in 2000 by chemist Ge Li as WuXi PharmaTech, the company expanded through acquisitions and re‑listings in 2018 after a 2015 take‑private. It produces a large part of the ingredients used in treatments for illnesses including leukemia, lymphoma, HIV, and obesity. As of 2025, the company reported around 39,000 employees and 6,000 customers. Its clients have included Jiangsu Hengrui, GlaxoSmithKline, AstraZeneca and Pfizer. Wikipedia
About WuXi AppTec Ord Shs H
CEOSteve Yang | Ge Li
Employees35,6 миң
Founded2000-ж., 1-дек.
Headquarters-
SectorHealth care
Websitewuxiapptec.com.cn